Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

Everett Vokes, MD
Published: Monday, Aug 14, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 
SELECTED
LANGUAGE


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x